Nano-therapeutics: A revolution in infection control in post antibiotic era

Zaidi, Sahar; Misba, Lama; Khan, Asad U.

doi:10.1016/j.nano.2017.06.015

Cited by 161 publications

(112 citation statements)

References 180 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…[6][7][8] Consequently, it is highly urgent to develop novel antibiotics against various life threatening bacterial pathogens. [13][14][15][16][17][18][19] Among the variety of engineered nanoparticles that have been used in antibacterial treatments, [13,[20][21][22] AgNP is the most widely explored antibacterial nanoagent due to its broad-spectrum antimicrobial properties and robust antimicrobial effectiveness AgNPs against two types of Gram-negative bacteria, E. coli and Pseudomonas aeruginosa (P. aeruginosa). The antibacterial action of the engineered NPs is generally involved with the surface-binding of the NPs to the bacteria, ion release, followed by the generation of high oxidative stress.…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, it becomes really difficult for bacterial cells to develop multiple simultaneous gene mutations to against NP-mediated treatments. [13][14][15][16][17][18][19] Among the variety of engineered nanoparticles that have been used in antibacterial treatments, [13,[20][21][22] AgNP is the most widely explored antibacterial nanoagent due to its broad-spectrum antimicrobial properties and robust antimicrobial effectiveness AgNPs against two types of Gram-negative bacteria, E. coli and Pseudomonas aeruginosa (P. aeruginosa). [43] The results showed that upon treatment with AgNPs, the surface charge of the bacteria moved toward neutral from −28.5 ± 2.9 to −3.5 ± 0.8 mV for E. coli, and from −20.6 ± 1.8 to −5.4 ± 0.5 mV for P. aeruginosa.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Antibacterial Activity of Silver Nanoparticles: Structural Effects

Tang

Zheng

2018

Adv Healthcare Materials

835

479

View full text Add to dashboard Cite

The increase of antibiotic resistance in bacteria has become a major concern for successful diagnosis and treatment of infectious diseases. Over the past few decades, significant progress has been achieved on the development of nanotechnology-based medicines for combating multidrug resistance in microorganisms. Among this, silver nanoparticles (AgNPs) hold great promise in addressing this challenge due to their broad-spectrum and robust antimicrobial properties. This review illustrates the antibacterial mechanisms of silver nanoparticles and further elucidates how different structural factors including surface chemistry, size, and shape, impact their antibacterial activities, which are expected to promote the future development of more potent silver nanoparticle-based antibacterial agents.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Antibacterial Activity of Silver Nanoparticles: Structural Effects

Tang

Zheng

2018

Adv Healthcare Materials

835

479

View full text Add to dashboard Cite

show abstract

“…Over the last few decades, NPs (with a nanometer scale size often ≤100 nm) have been increasingly investigated in the treatment of various diseases, notably cancers, wherefrom a novel discipline referred to as nanomedicine has emerged. Recently, NPs have gained lots of therapeutic interest in combatting drug‐resistant bacteria and biofilm infections . Besides their inherent antimicrobial properties, NPs may be engineered to deliver or sustain the release of antimicrobial drugs at the site of infection .…”

Section: Other Antimicrobial‐carrier Conjugatesmentioning

confidence: 99%

“…Recently, NPs have gained lots of therapeutic interest in combatting drug-resistant bacteria and biofilm infections. 228 Besides their inherent antimicrobial properties, NPs may be engineered to deliver or sustain the release of antimicrobial drugs at the site of infection. 229,230 The main advantages of NPs are their small and modifiable sizes, their high ratio of surface area to mass, their functionalizable structures, their adaptability to both hydrophobic and hydrophilic drug molecules, their high stability in physiological liquids, and their therapeutic sitespecific targeting.…”

Section: Nanocarrier-antimicrobial Conjugatesmentioning

confidence: 99%

Drug delivery systems designed to overcome antimicrobial resistance

Pham

Loupias

Dassonville‐Klimpt

et al. 2019

Medicinal Research Reviews

View full text Add to dashboard Cite

Antimicrobial resistance has emerged as a huge challenge to the effective treatment of infectious diseases. Aside from a modest number of novel anti‐infective agents, very few new classes of antibiotics have been successfully developed for therapeutic use. Despite the research efforts of numerous scientists, the fight against antimicrobial (ATB) resistance has been a longstanding continued effort, as pathogens rapidly adapt and evolve through various strategies, to escape the action of ATBs. Among other mechanisms of resistance to antibiotics, the sophisticated envelopes surrounding microbes especially form a major barrier for almost all anti‐infective agents. In addition, the mammalian cell membrane presents another obstacle to the ATBs that target intracellular pathogens. To negotiate these biological membranes, scientists have developed drug delivery systems to help drugs traverse the cell wall; these are called “Trojan horse” strategies. Within these delivery systems, ATB molecules can be conjugated with one of many different types of carriers. These carriers could include any of the following: siderophores, antimicrobial peptides, cell‐penetrating peptides, antibodies, or even nanoparticles. In recent years, the Trojan horse‐inspired delivery systems have been increasingly reported as efficient strategies to expand the arsenal of therapeutic solutions and/or reinforce the effectiveness of conventional ATBs against drug‐resistant microbes, while also minimizing the side effects of these drugs. In this paper, we aim to review and report on the recent progress made in these newly prevalent ATB delivery strategies, within the current context of increasing ATB resistance.

show abstract

“…Further examples of the applications of nanoparticles for delivery of natural products have been reviewed elsewhere [52,53]. One area that might be of relevance include potent natural antibiotics, which have limited use due to insolubility issues and have required new synthesis procedures to improve their bioavailability or use of delivery systems to improve targeting and reduce the induction of antibiotic resistance [57,58].…”

Section: Impact Of Drug-delivery Systems In Natural Product Researchmentioning

confidence: 99%

Delivering Natural Products and Biotherapeutics to Improve Drug Efficacy

et al. 2017

View full text Add to dashboard Cite

Due to the increasing problem of drug resistance, new and improved medicines are required. Natural products and biotherapeutics offer a vast resource for new drugs; however, challenges, including the cost and time taken for traditional drug discovery processes and the subsequent lack of investment from the pharmaceutical industry, are associated with these areas. New techniques are producing compounds with appropriate activity at a faster rate. While the formulation of these combined with drug-delivery systems offers a promising approach for expanding the drug developments available to modern medicine. Here, various classes of drug-delivery systems are described and the advantages they bring to small molecule and biotherapeutic targeting are highlighted. This is an attractive approach to the pharmaceutical industry and the rising trend in research in this area is examined in brief. New medicines are constantly being developed or repurposed, aimed at curing or preventing diseases or conditions where therapeutic product availability is lacking, or to reduce side effects, improve quality of life, reduce the burden on the cost of healthcare systems, while significantly extending patients' lives. However, drug discovery, research and development (R&D) can be an extensive process lasting over 7-10 years, with an average cost of $2.6 billion for each successful drug that reaches the market [1]. These substantial cost and time factors originate from the scientific, technical and regulatory challenges that are needed to fully understand the drug mechanisms of action and physiological interactions for complex diseases at molecular level. Achieving viable commercial success subsequently

show abstract

Nano-therapeutics: A revolution in infection control in post antibiotic era

Cited by 161 publications

References 180 publications

Antibacterial Activity of Silver Nanoparticles: Structural Effects

Antibacterial Activity of Silver Nanoparticles: Structural Effects

Drug delivery systems designed to overcome antimicrobial resistance

Delivering Natural Products and Biotherapeutics to Improve Drug Efficacy

Contact Info

Product

Resources

About